CN1057097C - 封阻补体激活的嵌合蛋白 - Google Patents

封阻补体激活的嵌合蛋白 Download PDF

Info

Publication number
CN1057097C
CN1057097C CN94194284A CN94194284A CN1057097C CN 1057097 C CN1057097 C CN 1057097C CN 94194284 A CN94194284 A CN 94194284A CN 94194284 A CN94194284 A CN 94194284A CN 1057097 C CN1057097 C CN 1057097C
Authority
CN
China
Prior art keywords
protein
chimeric protein
mcp
cell
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94194284A
Other languages
English (en)
Chinese (zh)
Other versions
CN1138863A (zh
Inventor
J·-L·高
P·J·希金斯
C·G·叶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THOUSAND YEARS MEDICAMENTS Inc
Original Assignee
CytoMed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CytoMed Inc filed Critical CytoMed Inc
Publication of CN1138863A publication Critical patent/CN1138863A/zh
Application granted granted Critical
Publication of CN1057097C publication Critical patent/CN1057097C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN94194284A 1993-09-24 1994-09-23 封阻补体激活的嵌合蛋白 Expired - Fee Related CN1057097C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12659693A 1993-09-24 1993-09-24
US126,596 1993-09-24
US08/310,416 US5679546A (en) 1993-09-24 1994-09-22 Chimeric proteins which block complement activation
US310,416 1994-09-22

Publications (2)

Publication Number Publication Date
CN1138863A CN1138863A (zh) 1996-12-25
CN1057097C true CN1057097C (zh) 2000-10-04

Family

ID=26824842

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94194284A Expired - Fee Related CN1057097C (zh) 1993-09-24 1994-09-23 封阻补体激活的嵌合蛋白

Country Status (9)

Country Link
US (2) US5679546A (https=)
EP (1) EP0723555B1 (https=)
JP (2) JP3860605B2 (https=)
CN (1) CN1057097C (https=)
AT (1) ATE380875T1 (https=)
AU (1) AU697167B2 (https=)
CA (1) CA2172610A1 (https=)
DE (1) DE69435049D1 (https=)
WO (1) WO1995008570A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
US5866402A (en) * 1995-05-05 1999-02-02 Chiron Corporation Chimeric MCP and DAF proteins with cell surface localizing domain
FR2736916B1 (fr) * 1995-07-21 1997-09-19 Univ Paris Curie Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
CA2298475A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US7112327B2 (en) * 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
JP4437192B2 (ja) * 1998-02-20 2010-03-24 タノックス インコーポレイテッド 補体活性化阻害剤
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
US6316253B1 (en) 1999-11-01 2001-11-13 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
EP2896631A1 (en) 2000-10-10 2015-07-22 Genentech, Inc. Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US6820011B2 (en) * 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
BR0209319A (pt) * 2001-06-08 2004-07-20 Novartis Ag Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina
EP1539811A4 (en) * 2002-09-16 2006-05-24 Elusys Therapeutics Inc PREPARATION OF BISPEQIFIC MOLECULES WITH POLYETHYLENE GLYCOL LINKER
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
WO2005069726A2 (en) 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
JP4914344B2 (ja) * 2004-03-31 2012-04-11 ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ 虚血／再灌流障害治療用のアドレノメデュリン及びアドレノメデュリン結合タンパク質
US8703693B2 (en) * 2004-03-31 2014-04-22 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
WO2006128006A1 (en) * 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
SG10201804008UA (en) * 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US7759304B2 (en) * 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
TW201716437A (zh) * 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子ｄ抗體及其用途
JP5332064B2 (ja) * 2007-03-01 2013-11-06 ウェルスタット イムノセラピューティクス， エルエルシー 炎症により特徴付けられる疾患の治療
CN101668773B (zh) 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2009151634A1 (en) * 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
CN102234332B (zh) * 2010-04-26 2014-12-17 浙江海正药业股份有限公司 一种重组人血白蛋白及其融合蛋白的分离纯化工艺
BR112012029067A2 (pt) 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
AU2011295715B9 (en) 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
EP3524258B1 (en) 2011-06-22 2025-10-01 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US9243070B2 (en) 2012-04-03 2016-01-26 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor Bb antibodies and uses thereof
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
CN110724691A (zh) 2014-02-27 2020-01-24 阿勒根公司 补体因子Bb抗体
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
EP3633371A1 (en) 2014-12-18 2020-04-08 F. Hoffmann-La Roche AG Assay and method for determining cdc eliciting antibodies
CN108291216B (zh) 2015-09-24 2022-09-16 宾夕法尼亚州大学信托人 用于治疗补体介导的疾病的组合物和方法
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
KR20180091097A (ko) * 2015-12-23 2018-08-14 그리노파티온 바이오테크 게엠베하 보체 활성화를 억제하기 위한 폴리펩티드
CA3029106A1 (en) 2016-06-28 2018-01-04 Universitat Ulm Complement inhibitors and uses thereof
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US20220195012A1 (en) * 2019-04-13 2022-06-23 National Centre For Cell Science Daf-mcp chimeric proteins, process to manufacture the same and use of the chimeric protein for treating pathological conditions involving the complement system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US4774180A (en) * 1986-02-26 1988-09-27 Massachusetts Institute Of Technology Construction and application of polyproteins
US5264357A (en) * 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
DE69007975T2 (de) * 1989-08-22 1994-07-21 Immunex Corp Fusionsprotein bestehend aus gm-csf und il-3.
CA2049964A1 (en) * 1990-01-26 1991-07-27 Biogen, Inc. C4 binding protein fusion proteins
EP1413587A2 (en) * 1991-05-03 2004-04-28 Washington University Modified complement system regulator
US5252216A (en) * 1992-03-24 1993-10-12 Smithkline Beecham Corporation Protein purification
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins

Also Published As

Publication number Publication date
EP0723555B1 (en) 2007-12-12
JP3860605B2 (ja) 2006-12-20
JP2005041882A (ja) 2005-02-17
WO1995008570A1 (en) 1995-03-30
EP0723555A4 (en) 1999-04-28
DE69435049D1 (de) 2008-01-24
CA2172610A1 (en) 1995-03-30
EP0723555A1 (en) 1996-07-31
ATE380875T1 (de) 2007-12-15
US5851528A (en) 1998-12-22
AU8071994A (en) 1995-04-10
CN1138863A (zh) 1996-12-25
JPH09502985A (ja) 1997-03-25
US5679546A (en) 1997-10-21
AU697167B2 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
CN1057097C (zh) 封阻补体激活的嵌合蛋白
CN1289526C (zh) 干细胞因子
WO1995008570A9 (en) Chimeric proteins which block complement activation
CN1341660A (zh) 一种新的多肽——人白细胞介素受体－配体(il－17b和il－17br)32.56和编码这种多肽的多核苷酸
HK1038377A (en) Stem cell factor
CN1326985A (zh) 一种新的多肽——人嘌呤受体21.23和编码这种多肽的多核苷酸
CN1341626A (zh) 一种新的多肽——结合蛋白RanBP2－14.52和编码这种多肽的多核苷酸
CN1343687A (zh) 一种新的多肽——转运蛋白17.05和编码这种多肽的多核苷酸
CN1331158A (zh) 一种新的多肽——人嘌呤受体9.46和编码这种多肽的多核苷酸
CN1347913A (zh) 一种新的多肽——人凝血栓蛋白29.37和编码这种多肽的多核苷酸
CN1352184A (zh) 一种新的多肽——人嘌呤受体9.68和编码这种多肽的多核苷酸
CN1326943A (zh) 一种新的多肽——结合蛋白RanBP236.85和编码这种多肽的多核苷酸
CN1331100A (zh) 一种新的多肽——结合蛋白RanBP15.29和编码这种多肽的多核苷酸
CN1345972A (zh) 一种新的多肽——枯草蛋白酶14.08和编码这种多肽的多核苷酸
CN1326944A (zh) 一种新的多肽——Symplekin8.91和编码这种多肽的多核苷酸
CN1326960A (zh) 一种新的多肽——糖基磷脂酰肌醇聚糖f10.89和编码这种多肽的多核苷酸
CN1364878A (zh) 一种新的多肽——人染色体精氨酸转运atp酶45.98和编码这种多肽的多核苷酸
CN1382710A (zh) 一种多肽——人转运蛋白－53.24和编码这种多肽的多核苷酸
CN1328030A (zh) 一种新的多肽——人抑癌基因98和编码这种多肽的多核苷酸
CN1351021A (zh) 一种新的多肽——结合蛋白RanBP10.23和编码这种多肽的多核苷酸
CN1300774A (zh) 一种新的多肽－人凝血栓蛋白46和编码这种多肽的多核苷酸
CN1510042A (zh) 一种多肽——人pax蛋白12和编码这种多肽的多核苷酸
CN1311210A (zh) 一种新的多肽——人锌指蛋白49和编码这种多肽的多核苷酸
CN1341646A (zh) 一种新的多肽——人大蛋白52.69和编码这种多肽的多核苷酸
CN1386751A (zh) 一种多肽——信使核糖核酸前体拼接因子－59.84和编码这种多肽的多核苷酸

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C53 Correction of patent of invention or patent application
COR Change of bibliographic data

Free format text: CORRECT: PATENTEE; FROM: CYTOMED, INC. TO: QIANNIAN MEDICINE CORP.

CP01 Change in the name or title of a patent holder

Patentee after: Thousand Years Medicaments Inc

Patentee before: Cytomed Inc.

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee